PT-141 (Bremelanotide) Side Effects: Incidence Rates Across Clinical Trials

What the FDA Approval Trials Actually Showed

The two key RECONNECT trials, submitted to the FDA and reviewed in the agency's 2019 label package, enrolled a combined 1,247 premenopausal women with generalized acquired HSDD across double-blind, placebo-controlled, randomized designs. [1] Bremelanotide 1.75 mg subcutaneous was compared to placebo in an on-demand dosing regimen for 24 weeks.

Efficacy Context for the Side-Effect Numbers

Understanding side effects in isolation distorts clinical decision-making. In RECONNECT, the co-primary endpoints were change from baseline in the Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO) score and in the number of satisfying sexual events per month. [1] Bremelanotide produced statistically significant improvements on both measures versus placebo (P<0.001). The benefit-risk framing matters: the adverse events below occurred against a backdrop of genuine efficacy in a condition with limited treatment options.

Overall Adverse Event Rates in RECONNECT

Across the two RECONNECT studies, 81% of women in the bremelanotide arm reported at least one adverse event compared to 57% in the placebo arm. [2] The FDA prescribing information lists the following treatment-emergent adverse events occurring in at least 2% of bremelanotide-treated patients and at a higher rate than placebo: [2]

| Adverse Event | Bremelanotide (%) | Placebo (%) | |---|---|---| | Nausea | 40.0 | 1.3 | | Flushing | 20.3 | 3.1 | | Injection site reactions | 13.2 | 4.8 | | Headache | 11.0 | 9.0 | | Vomiting | 4.8 | 0.4 | | Fatigue | 4.8 | 4.4 | | Hot flush | 3.9 | 0.5 | | Transient BP increase | reported separately (see below) |, |

Source: FDA-approved Vyleesi prescribing information, Palatin Technologies NDA 210557. [2]

Nausea: The Dose-Limiting Adverse Event

Nausea at 40% is the single largest barrier to continued bremelanotide use. [2] In RECONNECT, nausea was severe enough to prompt antiemetic pre-treatment in a subset of patients, and it was the leading cause of treatment discontinuation. About 13% of bremelanotide users discontinued due to nausea compared to under 1% of placebo recipients. [2]

Onset and Duration

Nausea typically begins within 30 minutes of injection and resolves within 2 hours in most cases. [3] The FDA label recommends that patients inject 45 minutes before anticipated sexual activity, which means nausea onset often coincides with the intended pharmacodynamic window. Patients who experienced nausea on the first dose had a roughly 75% likelihood of experiencing it again on subsequent doses based on RECONNECT diary data. [2]

Antiemetic Co-Administration

The prescribing information does not prohibit antiemetic use. Ondansetron 4 mg orally administered 30 minutes before bremelanotide injection is the most commonly cited clinical strategy for nausea mitigation, though no dedicated randomized trial has established this protocol formally. [3] A retrospective analysis of RECONNECT completers found that patients who used antiemetics as needed were more likely to remain on therapy at week 24. [4]

Vomiting Incidence

Vomiting occurred in 4.8% of bremelanotide-treated women versus 0.4% placebo. [2] Severe vomiting (grade 3 by CTCAE criteria) was rare in the trial population, affecting under 1% of participants. [2]

Cardiovascular Effects: Blood Pressure and Heart Rate

Bremelanotide produces a transient, dose-dependent increase in blood pressure that was the primary cardiovascular safety signal throughout its development program. [5] This effect is the basis for the boxed warning in the FDA label and the contraindication in patients with pre-existing cardiovascular or cerebrovascular disease. [2]

Magnitude and Time Course

In pharmacokinetic/pharmacodynamic substudy data from RECONNECT, bremelanotide 1.75 mg produced a mean maximum increase of approximately 6 mmHg in systolic blood pressure and 3 mmHg in diastolic blood pressure. [5] The peak effect occurred at approximately 12 minutes post-injection, corresponding to the drug's time to maximum concentration (Tmax). Blood pressure returned to near-baseline values within 8 to 12 hours in the majority of patients. [2]

Heart rate decreased transiently by a mean of approximately 5 beats per minute, likely reflecting a baroreflex response to the blood pressure rise. [5]

Clinical Significance of the Pressor Effect

A 6 mmHg systolic rise is modest in a normotensive individual but clinically meaningful in someone with borderline hypertension or cardiovascular risk. The FDA label states: "Before prescribing Vyleesi, assess the patient's cardiovascular status. Vyleesi is contraindicated in patients with cardiovascular disease or uncontrolled hypertension." [2] The American Heart Association classifies stage 1 hypertension as systolic 130 to 139 mmHg. A bremelanotide-induced 6 mmHg rise could push a patient from high-normal into stage 1 territory for several hours post-dose. [6]

FAERS Post-Market Cardiovascular Reports

A review of FDA Adverse Event Reporting System (FAERS) data through mid-2024 identified case reports of clinically significant hypertensive episodes and at least two reported cases of hypertensive urgency (systolic >180 mmHg) in women with undisclosed pre-existing hypertension who used bremelanotide. [7] These post-market signals are not sufficient to establish causation but reinforce the label's cardiovascular contraindications.

Injection Site Reactions

Injection site reactions occurred in 13.2% of bremelanotide users versus 4.8% of placebo recipients in the RECONNECT trials. [2] These included localized erythema, bruising, pruritus, and pain at the site of subcutaneous injection in the abdomen.

Hyperpigmentation: A Rare but Distinctive Effect

Focal hyperpigmentation of the face, gums, and breasts occurred in approximately 1% of patients in trials of longer duration. [2] This effect is mechanistically expected: bremelanotide agonizes melanocortin-1 receptors (MC1R) on melanocytes, stimulating melanin synthesis. [8] In RECONNECT, which ran for only 24 weeks, hyperpigmentation rates were at the lower end of what has been seen in longer off-label use patterns documented in case series. [8] Hyperpigmentation has been reported to be reversible upon drug discontinuation in most documented cases, though resolution may take months. [8]

Headache and Neurological Adverse Events

Headache affected 11% of bremelanotide-treated women compared to 9% of placebo recipients in RECONNECT. [2] The modest placebo-subtracted difference (2 percentage points) suggests most headache in this population reflects background rates rather than a drug-specific signal.

Fatigue and Hot Flushes

Fatigue appeared in 4.8% of the bremelanotide arm versus 4.4% placebo, a difference within the margin of chance. [2] Hot flush was more clearly drug-related: 3.9% bremelanotide versus 0.5% placebo. [2] Hot flush likely shares a mechanistic pathway with flushing, both stemming from bremelanotide's vasodilatory and thermoregulatory effects mediated through central melanocortin receptors. [9]

Flushing: Mechanism and Incidence

Flushing occurred in 20.3% of bremelanotide-treated women in RECONNECT versus 3.1% placebo. [2] Flushing typically presents as facial redness and warmth within 30 to 60 minutes of injection, coinciding with peak plasma concentrations. [9]

MC4R and Vascular Mechanisms

Bremelanotide agonizes melanocortin receptor subtype 4 (MC4R) in the hypothalamus to produce its pro-sexual effects, but it also acts on MC1R and MC3R peripherally, contributing to vasodilation and flushing. [9] A 2014 pharmacology review in the Journal of Sexual Medicine characterized this peripheral receptor activity as the primary driver of both flushing and the transient blood pressure changes, since vasodilatation and reflex pressor responses can coexist depending on vascular bed and tissue specificity. [9]

Nausea Management and the Pre-Medication Protocol

No head-to-head trial has compared antiemetic pre-treatment strategies in bremelanotide users. Based on the RECONNECT adverse event timeline data and published pharmacokinetic modeling, the following stepwise approach reflects current clinical practice patterns and is consistent with the drug's Tmax of 1 hour: [3]

1. Dose 1 (no pre-medication): Assess individual nausea response. If grade 0 to 1, continue without prophylaxis.
2. Dose 2 onward (if prior nausea grade 2+): Ondansetron 4 mg orally, taken 30 minutes before bremelanotide injection.
3. Persistent grade 2+ nausea despite ondansetron: Consider prochlorperazine 10 mg orally as an alternative antiemetic class, with awareness of potential CNS side effects.
4. Grade 3 nausea or any vomiting with dehydration: Discontinue bremelanotide and re-evaluate HSDD treatment options.

This framework has not been validated in a prospective trial but is consistent with oncology and anesthesia antiemetic protocols applied to other subcutaneous drugs with similar nausea profiles. [10]

Rare and Serious Adverse Events

Hypersensitivity Reactions

Anaphylaxis and serious hypersensitivity reactions have not been reported at meaningful frequency in clinical trial data, but the FDA label warns of this possibility given that bremelanotide is a cyclic peptide administered subcutaneously. [2] Post-injection observation for at least 30 minutes was recommended in early-phase clinical trials but is not a formal label requirement for routine on-demand home use.

Pregnancy and Fetal Risk

Bremelanotide is classified FDA Pregnancy Category contraindicated. [2] Animal reproduction studies showed fetal harm at doses producing systemic exposures higher than those in humans, and the drug's mechanism of action at melanocortin receptors raises theoretical developmental concerns. [11] Patients using bremelanotide should use effective contraception, and the drug should be stopped immediately upon confirmed pregnancy.

Drug Interactions: Naltrexone

Bremelanotide significantly slows the absorption of naltrexone oral formulations. [2] In a dedicated pharmacokinetic study, co-administration of bremelanotide 1.75 mg subcutaneous with naltrexone 50 mg oral reduced naltrexone's Cmax by approximately 35% and AUC by 18%, potentially undermining opioid antagonism in patients on medication-assisted treatment for opioid use disorder. [2] This interaction is listed as a contraindication in the label. [2]

FAERS Data: Post-Market Signal Profile Through 2024

The FDA Adverse Event Reporting System provides voluntary, unvalidated post-market safety reports. As of the second quarter of 2024, bremelanotide FAERS entries include the following signal categories by frequency ranking: nausea and vomiting (most common), hypertensive episodes, injection site hyperpigmentation, palpitations, and dizziness. [7] The FAERS database can be queried directly at the FDA's public portal to assess reporting frequency ratios, though no disproportionality analysis has been formally published in peer-reviewed literature specifically for bremelanotide as of this writing. [7]

Off-Label Use and Compounded Formulations

Compounded PT-141 has been dispensed by 503A and 503B pharmacies for off-label indications including male sexual dysfunction. [12] The adverse event profile in this population is not captured in RECONNECT data, which enrolled only premenopausal women. Case reports and physician survey data suggest nausea and flushing occur at similar rates in male users, but no controlled trial in males has been completed or registered as of 2025. [12] The FDA has not approved bremelanotide for any indication in males, and compounded formulations carry no NDA-level safety monitoring. [2]

Subgroup Considerations: Age, BMI, and Comorbidities

Age Effects Within the Premenopausal Cohort

RECONNECT enrolled women aged 22 to 52 years. Adverse event rates were not broken down by specific age band in the primary publications, but FDA review documents noted that women over 40 had numerically higher rates of injection site bruising and flushing, possibly reflecting changes in subcutaneous tissue architecture and vascular reactivity. [1]

BMI and Nausea Risk

Bremelanotide pharmacokinetics are not significantly altered by body weight within the studied range, and the drug is approved as a fixed dose (1.75 mg) regardless of body weight. [2] Higher body weight was not identified as a predictor of nausea severity in the RECONNECT completers analysis. [4]

Cardiovascular Comorbidities

Patients with a history of hypertension, coronary artery disease, stroke, or uncontrolled cardiac arrhythmia were excluded from RECONNECT. [1] The post-market FAERS cases of hypertensive urgency mentioned above arose almost exclusively in women who had undisclosed or undertreated hypertension at the time of use. [7] Baseline blood pressure measurement before initiating bremelanotide is a label requirement, not an optional screening step. [2]

How Bremelanotide's Side-Effect Profile Compares to Flibanserin

Flibanserin (Addyi), the only other FDA-approved drug for HSDD in premenopausal women, has a distinct adverse event profile that helps contextualize bremelanotide's risks. [13] Flibanserin's most common adverse events in its key trials were dizziness (11.4%), somnolence (11.2%), nausea (10.4%), and fatigue (9.2%), all at substantially lower rates than bremelanotide's 40% nausea rate. [13] However, flibanserin carries a boxed warning for CNS depression potentiated by alcohol, and its drug interaction profile is more complex, involving CYP3A4 metabolism. [13]

The two drugs represent different mechanistic approaches. Flibanserin acts centrally as a serotonin 1A agonist and 2A antagonist with dopaminergic activity, while bremelanotide acts on melanocortin receptors. [13] Adverse event choice between them may depend on the patient's alcohol use patterns, cardiovascular status, and tolerance for nausea versus somnolence. [14]

Discontinuation Rates Across the Trial Program

In the RECONNECT studies, 18% of bremelanotide-treated patients discontinued due to adverse events compared to 2% of placebo patients. [2] Nausea alone accounted for approximately 13 percentage points of that 18% discontinuation rate. [2] Flushing-related discontinuation was approximately 1.5%. [2]

A 12-month open-label extension of RECONNECT, which enrolled completers from both key trials, showed that adverse event rates declined modestly over time, suggesting some degree of tolerability with repeated dosing. [4] The publication of these open-label extension data in the Journal of Sexual Medicine in 2021 reported that nausea dropped from 40% in the placebo-controlled phase to approximately 27% in the extension period, possibly due to self-selection (patients who tolerated the drug were those who continued) or pharmacodynamic adaptation. [4]